Should You Buy Defensive Stocks British American Tobacco plc, GlaxoSmithKline plc & Centrica PLC?

Will Defensive Stocks British American Tobacco plc (LON:BATS), GlaxoSmithKline plc (LON:GSK) & Centrica PLC (LON:CNA) Outperform In 2016?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

World markets remain unstable despite the recent rally in equities . Investors looking to park capital in stocks that should perform ok in a prolonged bear market should be researching defensive plays. Historically defensive stocks have been in the consumer, utilities and healthcare sectors. The three stocks below are perfect defensive stocks that should hold up well in a downturn. 

Tobacco king

British American Tobacco (LSE: BATS) has been an outstanding performer since the year 2000, the share price has increased by a whopping 629% and the company has returned billions to shareholders in the form of dividends. The company manages to maintain margins of 30-36% and generate over £4bn in net profit each year.

Shareholders will see a substantial amount of this profit returned in a dividend of 154p a share (3.9%) which is covered 1.6 times by cash. The company is relatively cheap too — currently shares are trading on a P/E ratio of just over 17. This is lower than London’s other large tobacco stock Imperial Brands (LSE: IMB). 

British American Tobacco is a great stock to own in times like these because of the defensive nature of tobacco companies and the huge profit the company has consistently delivered for years. 

Pharma giant

GlaxoSmithKline (LSE: GSK) is an extremely popular defensive stock in the US and UK. The company operates in the healthcare sector and is expected to have revenues of over £25bn this year. Glaxo pays out a punchy 6% dividend and the shares still only trade on a P/E of 15, which is firmly in the bottom half of  its peer group.

The strong defensive qualities can be seen when looking at a 10 year chart for the stock — impressively the stock rose in during the 2008/2009 global financial crisis. This would suggest that if the world economy enters another recession then Glaxo shares would be a great place to have invested. 

The company has developed an exciting range of new drugs and treatments to help fill the revenue gap left by old treatments coming off patents. Although revenue is declining the company is keeping profits relatively steady, and the stock is definitely one to own in a downturn.  

UK utility

Utility stocks such as Centrica (LSE: CNE) are not something I would usually look at. However, in the current economic climate the sector may well outperform others by the end of the year. The headline attraction to Centrica is the 5.3% dividend yield but there could be a good turnaround story here.

After two years of losses the company is forecast to swing into a profit for 2016 and 2017 which could cause the shares to re-rate. The forecast P/E ratio for 2016 is 12.5 which is a good deal lower than its listed peers and that is something that I would expect to change. Centric has defensive qualities like the other stocks mentioned here but there is also considerable scope for capital growth. 

Centrica is reporting this week so that may give us some confirmation of the companies change in fortunes and the outlook going forward. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing For Beginners

1 FTSE 250 stock I like and 1 I’ll avoid after the stock market correction

Jon Smith analyses the move lower in certain FTSE 250 companies over the past month and picks one that looks…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Is April 2026 a great time to buy Lloyds shares?

Lloyds shares have been flying over the last two years. And there's one factor that could mean the bank continues…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Want to aim for a £500 second income each month? Here’s how much it takes

Christopher Ruane digs into the numbers and mechanics that could let someone with no shares today build an annual second…

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

Down 95%, what might it take for the Aston Martin share price to rise 2,000%?

The Aston Martin share price has collapsed. Our writer considers what it might take for it to regain some ground…

Read more »

Investing Articles

How are Diageo shares looking in April 2026?

It's been an eventful year so far, but what has the impact been for Diageo shares, and where might they…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

P/Es below 7! 3 staggeringly cheap shares despite yesterday’s rally

Investors who fear they have missed their opportunity to buy cheap shares as the stock market recovers might want to…

Read more »

ISA coins
Investing Articles

Want to know what UK investors have been buying in their ISAs?

Looking for stock, trust, and fund ideas this April? Royston Wild discusses what Brits have been stuffing in their Stocks…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Why aren’t people buying Greggs shares by the bucketload?

Greggs' shares remain in the doldrums. But should Foolish investors consider pouncing while others won't? Paul Summers takes a fresh…

Read more »